Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03447184
Other study ID # CS/BVMD/18/01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 26, 2018
Est. completion date March 1, 2019

Study information

Verified date July 2019
Source M? Ð?c Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Until now no scientific clinical evidence exists regarding the possible impact of long term endogenous androgen priming in IVF patients aligned with the Bologna Criteria, in specific the impact of priming on serum parameters correlated with the ovarian reserve, antral follicle count, and the number of retrievable follicles. Thus, this pilot-study will explore a new suggested protocol for the Bologna criteria patient developed from basic physiology, and will if successful result in a subsequent randomized controlled trial in the same subset of patients, enabling a possible paradigm shift in the treatment of poor ovarian response (POR).


Description:

A single center study pilot study in 30 IVF Bologna criteria POR patients. All patients fulfilling the ESHRE Bologna criteria will be eligible for inclusion.

Eight weeks prior to stimulation for IVF, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor daily will commence, concomitantly with GnRHa down-regulation with a depot GnRHa.

After 8 weeks, stimulation will be performed with a fixed dose of 300 IU rFSH (Gonal F, Merck) for the first 5 days in patients ≤ 34 years of age and 300 IU Pergoveris (Merck) in patients ≥ 35 years of age. The use of hCG and aromatase inhibitor will stop on the first day of stimulation.

Monitoring will be performed according to the standard procedure of the clinic. Patients will receive a bolus of 6.500 IU rhCG (Ovitrelle, Merck) for triggering of final oocyte maturation. Oocyte pick-up and embryo transfer will be performed according to the policy of the clinic. Oocyte pick-up (OPU) and embryo transfer will be performed according to standard procedures.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 1, 2019
Est. primary completion date February 18, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 41 Years
Eligibility Inclusion Criteria:

- Age 18 - 41 years

- BMI < 30 kg/m2

- Ovarian reserve, according to the ESHRE Bologna Criteria measured within two months prior to stimulation start

Bologna criteria: At least two of the following three features present:

- Advanced maternal age (=40 years) or any other risk factor for POR

- A previous POR (=3 oocytes with a conventional stimulation protocol)

- An abnormal ovarian reserve test (i.e. antral follicle count < 5-7 follicles or AMH< 0.5 - 1.1 ng/mL)

- Poor responder if - Two previous episodes of POR after maximal stimulation (300 IU)

- Receiving GnRH-antagonist co-treatment during ovarian stimulation

- Agreement to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study.

- Have given written informed consent with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.

Exclusion Criteria:

- Chronical medical conditions like Diabetes, Crohns disease, Thyroid disease, Hepatitis B and Sexually Transmitted Diseases Simultaneous participation in an interventional clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Androgen priming
Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B. Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3ß-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor

Locations

Country Name City State
Vietnam Lan N Vuong Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
M? Ð?c Hospital

Country where clinical trial is conducted

Vietnam, 

References & Publications (1)

Vuong TNL, Ho MT, Ha TQ, Jensen MB, Andersen CY, Humaidan P. Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles. J Assist Reprod Genet. 2017 Apr;34(4):471-478. doi: 10.1007/s10815-017-0891-9. Epub 2017 Feb 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Follicular fluid concentration of estradiol Aspiration of follicular fluid while doing ovum pick-up Up to one hour after ovum pick-up
Other Follicular fluid concentration of androstenedione Aspiration of follicular fluid while doing ovum pick-up Up to one hour after ovum pick-up
Other Follicular fluid concentration of testosterone Aspiration of follicular fluid while doing ovum pick-up Up to one hour after ovum pick-up
Other Follicular fluid concentration of progesterone Aspiration of follicular fluid while doing ovum pick-up Up to one hour after ovum pick-up
Other Follicular fluid concentration of inhibin B Aspiration of follicular fluid while doing ovum pick-up Up to one hour after ovum pick-up
Other Cumulus and mural Luteinising hormone receptor (LHR) gene expression Cumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of LHR gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression. Up to one hour after ovum pick-up
Other Cumulus and mural 3ß-hydroxy-steroid-dehydrogenase (3ßHSD) gene expression Cumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of 3ßHSD gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression. Up to one hour after ovum pick-up
Other Cumulus and mural inhibin-Ba (INHB-A) receptor gene expression Cumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of INHB-A gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression. Up to one hour after ovum pick-up
Other Cumulus and mural androgen receptor gene expression Cumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of androgen receptor gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression. Up to one hour after ovum pick-up
Other Cumulus and mural FSH receptor gene expression Cumulus and mural granulosa cells from oocyte from the first follicle in each women were isolated immediately after ovum pick-up and snap frozen for analysis of FSH receptor gene expression. qPCR was performed and calculation of the expression level of the gene of interest was carried out according to the comparative method, normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for relative quantification of gene expression. Up to one hour after ovum pick-up
Primary Serum concentrations of AMH Blood sampling 8 weeks after starting androgen priming
Secondary Number of antral follicles Follicles 2-10mm on ultrasound 8 weeks after starting androgen priming
Secondary Serum concentrations of testosterone Blood sampling Up to 2 weeks after starting FSH stimulation
Secondary Serum concentrations of hCG Blood sampling Up to 2 weeks after starting FSH stimulation
Secondary Serum concentrations of progesterone Blood sampling Up to 2 weeks after starting FSH stimulation
Secondary Number of antral follicles Follicles 2-10 mm on ultrasound Up to 2 weeks after starting FSH stimulation
Secondary Number of pre-ovulatory follicles Follicles >/= 14 mm on ultrasound Up to 2 weeks after starting FSH stimulation
See also
  Status Clinical Trial Phase
Completed NCT03433768 - Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response N/A
Recruiting NCT05601193 - Ovarian PRP Injection in Women With POR N/A
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT04013984 - Acupuncture for Treatment of Patients With Poor Ovarian Response N/A
Completed NCT01816321 - Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial Phase 3
Recruiting NCT04310293 - Novel Therapy for Poor Responders Management N/A
Completed NCT05703308 - Menstrual Blood Stem Cells in Poor Ovarian Responders Phase 3
Terminated NCT00878124 - How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome N/A
Not yet recruiting NCT06089395 - The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR) Early Phase 1
Completed NCT01732068 - Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol Phase 2
Completed NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders Phase 2
Recruiting NCT04717752 - A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve N/A
Recruiting NCT04024722 - Improving in Vitro Fertilization in Women With Poor Ovarian Response N/A
Completed NCT03994614 - the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR) N/A
Recruiting NCT03830697 - A Trial Study on Acupuncture Treatment of Poor Ovarian Response N/A
Recruiting NCT02801591 - Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET N/A
Recruiting NCT04273256 - Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT02993588 - Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders Phase 2/Phase 3
Terminated NCT02418572 - Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Phase 3